Fabry in the older patient: Clinical consequences and possibilities for treatment

• Published in: Molecular genetics and metabolism Vol. 118; no. 4; pp. 319 - 325
• Main Authors: Lidove, Olivier, Barbey, Frédéric, Niu, Dau-Ming, Brand, Eva, Nicholls, Kathleen, Bizjajeva, Svetlana, Hughes, Derralynn A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2016
• Subjects: Adolescent; Adult; Agalsidase alfa; Age Factors; Aged; Aged, 80 and over; alpha-Galactosidase - administration & dosage; alpha-Galactosidase - adverse effects; Disease burden; Elderly; Enzyme replacement therapy; Enzyme Replacement Therapy - adverse effects; Fabry disease; Fabry Disease - complications; Fabry Disease - drug therapy; Fabry Disease - physiopathology; Female; Heart Diseases - chemically induced; Heart Diseases - physiopathology; Humans; Kidney Diseases - chemically induced; Kidney Diseases - physiopathology; Male; Middle Aged; Sex Characteristics; eGFR; LVMI; ERT; Fabry disease; FOS; MWT; MDRD; Disease burden; CKD EPI; Enzyme replacement therapy; α-Gal A; Agalsidase alfa; Elderly; LVH

Baseline demographic and phenotypic characteristics of patients aged ≥50years in the Fabry Outcome Survey (Shire; data extracted June 2014) were compared with younger adults to investigate potential factors influencing treatment decisions in later life. Age groups were defined using age at treatment...